Research
Hormonal
Oral semaglutide 50 mg once daily results in 17.4% weight loss in people with obesity without type 2 diabetes.
For those who prefer not to inject medication, oral semaglutide 50 mg once daily can achieve 17.4% weight loss in people with obesity without diabetes, comparable to the injectable version.
GoodSupportsHIGH confidence
In people with obesity without T2D, a 68-week phase 3 trial (OASIS-1) assessed the safety and efficacy of oral semaglutide 50 mg once daily vs. placebo... Oral semaglutide 50 mg resulted in 17.4% WL compared to 1.8% with placebo
Why this rating
Based on phase 3 trial data.
Source
What is the pipeline for future medications for obesity?
Eka Melson et al. · International Journal of Obesity · 2024
DOI 10.1038/s41366-024-01473-y
narrative_reviewCited 286×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →